source
- FDA approves AstraZeneca's oral SERD Etcamah for HR+/HER2-negative advanced breast cancerFDA granted approval to AstraZeneca's camizestrant, marketed as Etcamah, an oral selective estrogen receptor degrader (SERD) for a specific subset of advanced breast cancer patients. The indicatio…
- BrainChild Bio secures $119M Series A to advance CAR-T therapy for deadly pediatric brain tumorBrainChild Bio announced a $119 million Series A financing round aimed at moving its CAR‑T programs for central nervous system cancers in children forward. The company’s lead candidate, BCB-276, w…